Should you buy Editas Medicine stock now?
Yes, the technical signal for Editas Medicine is currently BUY. Editas Medicine trades at $2.94 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is negative (bearish trend) at -0.095 with falling momentum (signal: -0.082); RSI is at 46.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $6.00 points to 104.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Editas Medicine stock?
The average analyst price target for Editas Medicine is $6.00. The current price is $2.94, which gives an upside of 104.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $5.40 and $6.60.
Is Editas Medicine a dividend stock?
No, Editas Medicine does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Editas Medicine stock?
Editas Medicine is rated as a stock with extreme risk. the annual standard deviation is 90.5%, which classifies the stock as extreme risk.
Is Editas Medicine overvalued?
No, Editas Medicine is considered undervalued based on the analyst price target (104.1% upside). Editas Medicine has the following valuation ratios: a P/S ratio of 11.0, a P/B ratio of 89.8. The analyst price target suggests that the stock is undervalued by 104.1%.
Is Editas Medicine overbought?
No, Editas Medicine is not overbought. RSI is at 46.1 (neutral zone). The technical indicators show: RSI is at 46.1 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.2% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Editas Medicine earnings report?
Editas Medicine reports its next earnings on August 11, 2026. The stock currently trades at $2.94.
Is Editas Medicine shorted?
Yes, Editas Medicine is shorted with 14.5% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Editas Medicine stock?
No, insiders are not buying Editas Medicine shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 4 sales. On a net basis, 57,910 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 133,112 $ sold. Active sellers include Burkly Linda, Parison Amy, O'Neill Gilmore Neil and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Editas Medicine a good stock?
Based on our total score, Editas Medicine is rated as a disastrous stock with a total score of 17 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 5/100, Momentum: 29/100. In addition: analysts see 104.1% upside to the price target; technical signal: Buy. Whether Editas Medicine is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Editas Medicine stock?
The outlook for Editas Medicine based on current data: the average analyst price target is $6.00 (+104.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/11/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Editas Medicine stock rising?
Editas Medicine is rising right now. The technical indicators show: the price is 3.2% above the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 14.5% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Editas Medicine go?
The average analyst price target for Editas Medicine is $6.00, which corresponds to a potential gain of 104.1% from the current price of $2.94. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Editas Medicine fall?
We lack enough history to give a specific floor for Editas Medicine. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Editas Medicine do?
edit.us driver en klinisk virksomhed, der udvikler genetiske lægemidler. De bruger CRISPR-teknologi til at redigere genomer og behandle alvorlige sygdomme. edit.us fokuserer især på arvelig blindhed og blodsygdomme. For eksempel arbejder de med EDIT-101 mod en type medfødt bli... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Editas Medicine as an investment.
Did Editas Medicine raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Editas Medicine. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Editas Medicine making money or losing money?
No, Editas Medicine is currently not making money — the company is losing money with a negative profit margin of -281.6%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Editas Medicine go bankrupt?
The bankruptcy risk of Editas Medicine is rated as elevated. Altman Z2 (a model for assessing financial distress) is -20.93 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 154% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Editas Medicine have a lot of debt?
Yes, Editas Medicine has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 154%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
